Trevena Inc (NASDAQ:TRVN) – Analysts at Jefferies Financial Group lifted their FY2018 earnings per share estimates for Trevena in a research report issued to clients and investors on Wednesday, October 10th. Jefferies Financial Group analyst B. Amin now forecasts that the biopharmaceutical company will post earnings of ($0.63) per share for the year, up from their prior estimate of ($0.64). Jefferies Financial Group currently has a “Hold” rating and a $1.00 target price on the stock. Jefferies Financial Group also issued estimates for Trevena’s Q4 2018 earnings at ($0.18) EPS, FY2019 earnings at ($0.43) EPS, FY2020 earnings at ($0.44) EPS, FY2021 earnings at ($0.41) EPS and FY2022 earnings at ($0.37) EPS.
Several other brokerages also recently weighed in on TRVN. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Trevena in a research report on Monday, August 13th. Zacks Investment Research raised shares of Trevena from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research report on Friday, August 17th. JMP Securities lifted their target price on shares of Trevena from $4.00 to $15.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Needham & Company LLC downgraded shares of Trevena from a “buy” rating to a “hold” rating in a research report on Friday. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $5.66.
Shares of TRVN opened at $0.85 on Monday. The company has a market cap of $161.29 million, a P/E ratio of -0.74 and a beta of -0.38. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 0.28. Trevena has a twelve month low of $0.76 and a twelve month high of $3.58.
Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $2.50 million for the quarter, compared to the consensus estimate of $5.50 million.
A number of large investors have recently bought and sold shares of the business. Millennium Management LLC grew its position in Trevena by 112.3% in the 2nd quarter. Millennium Management LLC now owns 1,005,820 shares of the biopharmaceutical company’s stock worth $1,448,000 after purchasing an additional 532,129 shares during the period. Paloma Partners Management Co bought a new stake in Trevena in the 2nd quarter worth approximately $411,000. Renaissance Technologies LLC grew its position in Trevena by 264.1% in the 2nd quarter. Renaissance Technologies LLC now owns 521,700 shares of the biopharmaceutical company’s stock worth $751,000 after purchasing an additional 378,400 shares during the period. FMR LLC grew its position in Trevena by 24.0% in the 2nd quarter. FMR LLC now owns 5,288,100 shares of the biopharmaceutical company’s stock worth $7,615,000 after purchasing an additional 1,022,830 shares during the period. Finally, GSA Capital Partners LLP grew its position in Trevena by 186.2% in the 2nd quarter. GSA Capital Partners LLP now owns 351,847 shares of the biopharmaceutical company’s stock worth $507,000 after purchasing an additional 228,900 shares during the period. 43.08% of the stock is owned by institutional investors and hedge funds.
Trevena Company Profile
Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.
See Also: Return on Equity (ROE)
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.